FREE Daily Stock Alerts From Stock-PR.com
DARA BioSciences reported today that SurgiVision, Inc., a privately held company, and Brainlab AG, announced on April 11 a collaboration aimed at integrating SurgiVision’s ClearPoint(NYSE:R) product line with Brainlab’s iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under magnetic resonance imaging (MRI) guidance. DARA presently owns over 500,000 shares and warrants of SurgiVision. Last June, SurgiVision received 510(k) clearance from the Food and Drug Administration (FDA) to market their ClearPoint system in the United States for general neurological interventional procedures.
More articles from Stock-PR.com are available for you to read at: http://stock-pr.com/?p=16769